


Original Article



Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China*

MA Yan^{1,&}, ZHU Dong Shan^{2,&}, CHEN Ren Bo^{1,&}, SHI Nan Nan^{1,&}, LIU Si Hong^{3,&}, FAN Yi Pin¹, WU Gui Hui⁴, YANG Pu Ye⁵, BAI Jiang Feng⁶, CHEN Hong⁷, CHEN Li Ying⁸, FENG Qiao⁹, GUO Tuan Mao¹⁰, HOU Yong¹¹, HU Gui Fen¹², HU Xiao Mei¹³, HU Yun Hong¹⁴, HUANG Jin¹⁵, HUANG Qiu Hua¹⁵, HUANG Shao Zhen¹⁶, JI Liang¹⁷, JIN Hai Hao¹⁸, LEI Xiao¹⁹, LI Chun Yan²⁰, LI Min Qing²¹, LI Qun Tang²², LI Xian Yong²³, LIU Hong De²⁴, LIU Jin Ping²⁵, LIU Zhang²⁶, MA Yu Ting²⁷, MAO Ya²⁸, MO Liu Fen²⁹, NA Hui³⁰, WANG Jing Wei³⁰, SONG Fang Li³¹, SUN Sheng³², WANG Dong Ting³³, WANG Ming Xuan³⁴, WANG Xiao Yan³⁵, WANG Yin Zhen³⁶, WANG Yu Dong³⁷, WU Wei³⁸, WU Lan Ping³⁹, XIAO Yan Hua⁴⁰, XIE Hai Jun⁴¹, XU Hong Ming⁴², XU Shou Fang⁴³, XUE Rui Xia⁴⁴, YANG Chun⁴⁵, YANG Kai Jun⁴⁶, YUAN Sheng Li⁴⁷, ZHANG Gong Qi⁴⁸, ZHANG Jin Bo⁴⁹, ZHANG Lin Song⁵⁰, ZHAO Shu Sen⁵¹, ZHAO Wan Ying⁵², ZHENG Kai⁵³, ZHOU Ying Chun⁵⁴, ZHU Jun Teng⁵⁵, ZHU Tian Qing⁵⁶, ZHANG Hua Min^{57,#}, WANG Yan Ping^{1,#}, WANG Yong Yan^{1,#}, and on behalf of 'Lung cleansing & detoxifying decoction' Emergency Project Expert Group for COVID-19

1. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China; 2. Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China; 3. Institute of Information on Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China; 4. Department of Tuberculosis, The Public Health Clinical Center of Chengdu, Chengdu 610066, Sichuan, China; 5. Department of Infectious Disease, Shaanxi Infectious Disease Hospital, Xi'an 610113, Shaanxi, China; 6. Department of Infectious Disease, Yulin Chinese Medicine Hospital, Yulin 719000, Shaanxi, China; 7. President's Office, The First Hospital of Qiqihar, Qiqihar 161005, Heilongjiang, China; 8. Department of Traditional Chinese Medicine, Shangluo Central Hospital, Shangluo 726000, Shaanxi, China; 9. Department of Traditional Chinese Medicine, The People's Hospital of Qitaihe, Qitaihe 154603, Heilongjiang, China; 10. Department of Scientific Research, Xianyang Central Hospital, Xianyang 712000, Shaanxi, China; 11. Department of traditional Chinese medicine, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei 230012, Anhui, China; 12. Department of Infectious Disease, Heping Hospital Affiliated to Changzhi Medical College, Changzhi 046000, Shanxi, China; 13. Department of Traditional Chinese Medicine, Langfang Hospital of Chinese Medicine, Langfang 065000, Hebei, China; 14. Department of Traditional Chinese Medicine, Xingtai Hospital of Chinese Medicine, Xingtai 054001, Hebei, China; 15. Department of Traditional Chinese Medicine, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 168600, Guangxi, China; 16. Department of Traditional Chinese Medicine, The First People's

*This study was supported by the 'National Major Science and Technology Projects of China' [2018ZX10101001-005-003, 2018ZX10101001-005-004].

&These authors contributed equally to this work.

#Correspondence should be addressed to Prof. WANG Yong Yan, PhD, 86-10-64089808, E-mail: wangyongyan1938@126.com; Prof. WANG Yan Ping, PhD, 86-10-64087789, E-mail: wangyanping4816@163.com; Prof. ZHANG Hua Min, PhD, 86-10-64032658, E-mail: zhanghm@mail.cintcm.ac.cn

Biographical notes of the first authors: MA Yan, female, born in 1980, MD, majoring in epidemiology, prevention and control of infectious disease; ZHU Dong Shan, male, born in 1982, PhD, longitudinal study and life course epidemiology; CHEN Ren Bo, male, born in 1980, PhD, majoring in diagnosis and treatment of chronic pathology in Chinese medicine; SHI Nan Nan, female, born in 1982, PhD, majoring in prevention and control of infectious disease, formulation of clinical practice Guidelines for Traditional Chinese Medicine; LIU Si Hong, female, born in 1989, PhD, majoring in data mining of Traditional Chinese Medicine literature.

Hospital of Fangchenggang, Fangchenggang 538001, Guangxi, China; 17. Department of Traditional Chinese Medicine, Mianyang Hospital of Traditional Chinese Medicine, Mianyang 621000, Sichuan, China; 18. Department of Traditional Chinese Medicine, Liuzhou People's Hospital, Liuzhou 545006, Gansu, China; 19. Department of Traditional Chinese Medicine, Affiliated Hospital of North Sichuan Medical College, Nanyun 637000, Sichuan, China; 20. Department of Infectious Disease, Yan'an Second People's Hospital, Yan'an 716000, Shaanxi, China; 21. Department of Traditional Chinese Medicine, Dazhou Central Hospital, Dazhou 635000, Sichuan, China; 22. Chongqing Traditional Chinese Medicine Hospital, Chongqing 400011, China; 23. The Second People's Hospital of Neijiang, Neijiang 641000, Sichuan, China; 24. Shijiazhuang Fifth Hospital, Shijiazhuang 050021, Hebei, China; 25. Department of Infectious Disease, The Fourth People's Hospital of Taiyuan, Taiyuan 030053, Shanxi, China; 26. Department of Traditional Chinese Medicine, The First Hospital of Suihua City, Suihua 152053, Heilongjiang, China; 27. Department of Traditional Chinese Medicine, The Fourth People's Hospital of Nanning, Nanning 530023, Guangxi, China; 28. Department of Infectious Disease, Ankang Hospital of Traditional Chinese Medicine, Ankang 725000, Shaanxi, China; 29. Department of Infectious Disease, Beihai Hospital of Chinese Medicine, Beihai 536000, Guangxi, China; 30. Department of Infectious Disease, Harbin Infectious Disease Hospital, Harbin 150036, Heilongjiang, China; 31. Department of Infectious Disease, The Third People's Hospital of Linfen, Linfen 041000, Shanxi, China; 32. Department of Traditional Chinese Medicine, Chengde Hospital of Traditional Chinese Medicine, Chengde 067000, Hebei, China; 33. Department of Infectious Disease, Datong Fourth Hospital, Datong 037008, Shanxi, China; 34. Department of Traditional Chinese Medicine, Suining Central Hospital, Suining 629000, Sichuan, China; 35. Department of Infectious Disease, Jinzhong Infectious Disease Hospital, Jinzhong 030600, Shanxi, China; 36. Department of Infectious Disease, Jincheng People's Hospital, Jincheng 048026, Shanxi, China; 37. Hengshui Hospital of Chinese Medicine, Hengshui 053000, Hebei, China; 38. President's office, Hanzhong Central Hospital, Hanzhong 723000, Hubei, China; 39. Department of Infectious Disease, Shuozhou People's Hospital, Shuozhou 036002, Shanxi, China; 40. Department of Traditional Chinese Medicine, Mudanjiang Kangan Hospital, Mudanjiang 157011, Heilongjiang, China; 41. Department of Infectious Disease, Xinzhou People's Hospital, Xinzhou 034000, Shanxi, China; 42. Department of Infectious Disease, Daqing Second Hospital, Daqing 163000, Heilongjiang, China; 43. Department of Traditional Chinese Medicine, Jiamusi Infectious Disease Hospital, Jiamusi 154007, Heilongjiang, China; 44. Department of Infectious Disease, Yuncheng Second Hospital, Yuncheng 044000, Shanxi, China; 45. Department of Traditional Chinese Medicine, Hanzhong Hospital for Infectious Diseases, Hanzhong 723000, Hubei, China; 46. Department of medical administration, The Third People's Hospital of Yangquan, Yangquan 045000, Shanxi, China; 47. Department of Traditional Chinese Medicine, Zhangjiakou Hospital of Traditional Chinese Medicine, Zhangjiakou 075000, Hebei, China; 48. Department of Traditional Chinese Medicine, Baoji Central Hospital, Baoji 721000, Shaanxi, China; 49. Department of Infectious Disease, Xi'an Chest Hospital, Xi'an 710100, Shaanxi, China; 50. Department of Traditional Chinese Medicine, Hospital (T-C-M) Affiliated to Southwest Medical University, Luzhou 646000, Sichuan, China; 51. Department of Traditional Chinese Medicine, Qiqihar Institute for The Prevention and Treatment of Infectious Diseases, Qiqihar 161006, Heilongjiang, China; 52. Department of Traditional Chinese Medicine, Hegang Infectious Hospital, Hegang 154000, Heilongjiang, China; 53. Fenyang Hospital of Shanxi Province, Fenyang 032200, Shanxi, China; 54. Department of Infectious Disease, Shuangyashan People's Hospital, Shuangyashan 230502, Heilongjiang, China; 55. Department of Rehabilitation Medicine, The Affiliated Hospital of Putian College, Putian 351100, Fujian, China; 56. Department of Infectious Disease, The Greater Khingan Range People's Hospital, Great Khingan 165000, Heilongjiang, China; 57. Institute of Chinese Materia Medica, China; Academy of Chinese Medical Sciences, Beijing 100000, China

Abstract

Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains unclear.

Methods A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients' medical records. Multivariable logistic regression models were used to estimate the odds ratio (OR) and 95% confidence interval (95% CI) of the associations between comorbidities (cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of COVID-19.

Results Overall, 158 (13.6%) patients were diagnosed with severe illness and 32 (2.7%) had unfavorable outcomes. Hypertension (2.87, 1.30–6.32), type 2 diabetes (T2DM) (3.57, 2.32–5.49), cardiovascular disease (CVD) (3.78, 1.81–7.89), fatty liver disease (7.53, 1.96–28.96), hyperlipidemia (2.15, 1.26–3.67), other lung diseases (6.00, 3.01–11.96), and electrolyte imbalance (10.40, 3.00–26.10) were independently linked to increased odds of being severely ill. T2DM (6.07, 2.89–12.75), CVD (8.47, 6.03–11.89), and electrolyte imbalance (19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission (5.46, 3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes (6.58, 1.46–29.64) within two weeks.

Conclusion Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.

Key words: Comorbidities; COVID-19; Severity; Gender; Age; Treatment outcome

Biomed Environ Sci, 2020; 33(12): 893-905 doi: 10.3967/bes2020.123

ISSN: 0895-3988

www.besjournal.com (full text)

CN: 11-2816/Q

Copyright ©2020 by China CDC

INTRODUCTION

The outbreak of coronavirus disease 2019 (COVID-19) has resulted in a pandemic that has led to a worldwide health crisis. Studies have reported that patients admitted to the intensive care unit (ICU) had a higher number of comorbidities (72.2%) than those not admitted to the ICU (37.3%)^[1]. Hence, the presence of a comorbidity has been considered to be a risk factor for mortality due to COVID-19.

One systematic review reported that hypertension, diabetes, chronic obstructive pulmonary disease (COPD), and cardiovascular diseases (CVDs) were related to the severity of COVID-19, while no association between liver disease, renal disease, or non-cardiometabolic diseases and clinical severity of COVID-19 was observed^[2]. In addition, limited by only a few studies comparing the comorbidities of patients with severe and non-severe COVID-19, subgroup analyses could not be analyzed by gender and age groups. Two recent studies have found that patients with comorbidities had unfavorable outcomes (defined as admission to an ICU, invasive ventilation, or death) compared to those without any comorbidities^[3,4]. However, one study did not separate specific components of comorbidity, and the other only included patients with overlapping hypertension, diabetes, and COPD. For one thing, how non-cardiometabolic disease comorbidities affect the risk of COVID-19 remains unclear. In addition, the independent role

of these components contributes to the risk of COVID-19 (e.g., which component has the strongest power of prediction of severity and treatment outcomes), due to the substantial overlap between them^[5].

Based on a retrospective cohort study that enrolled patients from nine provinces of China, we examined the association between specific components of comorbidities (overlapped and un-overlapped, including cardiometabolic diseases and non-cardiometabolic diseases), number of comorbidities, and clinical severities, as well as treatment outcomes of COVID-19. Subgroup analyses by gender and age were also performed.

METHODS

Study Population and Area

A retrospective follow-up design was adopted in this study. Laboratory-confirmed hospitalized patients aged 18–87 years were enrolled from 53 hospitals in nine provinces of China (Anhui, Fujian, Guangxi, Hebei, Heilongjiang, Shaanxi, Sichuan, Shanxi, and Chongqing) between January 13 and April 13, 2020. Each patient was followed up for a fixed period of two weeks to observe treatment outcomes. Information on demographics, medical histories, first-onset symptoms of COVID-19, diagnosis of clinical severity on admission, treatment regimen, and progression of disease during the two-week follow up were collected from the patients' medical records.

Comorbidities

Patients' comorbidities were self-reported (such as a history of stroke) or diagnosed (such as hypertension) on admission. In this study, comorbidities were divided into cardiometabolic and non-cardiometabolic diseases. Cardiometabolic comorbidities (present or not) included hypertension, type 2 diabetes (T2DM), heart disease, stroke, CVD (either heart disease or stroke), fatty liver disease, hyperlipidemia, and hyperuricemia. Non-cardiometabolic comorbidities included other lung diseases (pulmonary emphysema, bronchitis, and COPD), allergic diseases, hepatitis B, pulmonary tuberculosis (active or obsolete), electrolyte imbalance (e.g., hyponatremia and/or hypokalemia), abnormal liver or kidney function, and depression. The number of comorbidities was categorized as follows: none, one, two, and three or more comorbidities.

Clinical Severity and Treatment Outcome

COVID-19 severity was determined according to the *Diagnosis and Treatment Protocol for COVID-19 (seventh edition)*^[6].

Briefly, three types of severity were defined by the protocol:

- 1) Mild cases, mild clinical symptoms and no signs of pneumonia observed on CT image.
- 2) Moderate cases, only have fever and respiratory symptoms with radiological findings of pneumonia on CT image.
- 3) Severe cases, having any of the following: (a) respiratory distress and needs invasive ventilation, (b) pulse oxygen saturation $\leq 93\%$, or (c) arterial partial pressure of oxygen (PaO_2)/oxygen concentration ≤ 300 mmHg.

In the present study, mild and moderate cases were classified as non-severe cases, and COVID-19 patients were categorized as non-severe and severe cases.

The treatment outcomes of all patients were assessed at the end of the two-week follow-up and were categorized as either favorable or unfavorable outcomes. Patients with favorable outcomes were defined as having recovered or having improved condition at the end of the two-week follow-up window. Patients with unfavorable outcomes were defined as having died of COVID-19 or aggravated condition (e.g., disease progressed from moderate illness to severe illness) at the end of the two-week follow-up window.

Covariates

The following factors were used as covariates in

the analyses: age, sex, Body Mass Index (BMI), ever visited Wuhan city, first-onset symptoms of COVID-19, and unfavorable outcome. Age was categorized as < 60 and ≥ 60 years. Sex was categorized as male or female. BMI was calculated as weight in kilograms divided by height in meters squared (kg/m^2)^[7]. Ever went to Wuhan City was defined as ever going to Wuhan from December 2019 and thereafter. The first-onset symptoms of COVID-19 (present or not) included fever, fatigue, cough, congestion or runny nose, anorexia, sore throat, diarrhea, shortness of breath, and chills. Unfavorable outcome was defined as having any of the following: 1) patients deteriorated such as patients with advanced symptom, or were transferred to the ICU or superior hospitals to receive further treatment; 2) death.

Statistical Analysis

Patients' characteristics on admission are presented as means and standard deviation or median (interquartile: Q1, Q3) for continuous variables and percentages (%) for categorical variables. We used multivariable logistic regression models to estimate the odds ratio (OR) and 95% confidence interval (95% CI) for the associations between comorbidities (present or not and number of comorbidities) and clinical severity as well as treatment outcome of COVID-19. Patients with no comorbidities were used as the reference group for comparison with patients with any comorbidities. Non-severe patients were used as the reference group for clinical severity, and patients with favorable outcomes were used as the reference group for treatment outcome. Province-level variability was included in the model as a random effect.

We first analyzed the associations of overlapping components of comorbidities with clinical severity and treatment outcome. We then analyzed the un-overlapped associations between them to assess the independent role of each comorbidity component. We also separated the analyses by sex (male and female) and age (< 60 and ≥ 60 years). All statistical models were adjusted for age, sex, BMI, and first-onset symptoms of COVID-19. When analyzing the association between comorbidities and treatment outcomes, treatment regimens during follow-up were further adjusted.

The SURVEYLOGISTIC procedure was performed with the logit link that estimates sampling errors based on the clustered sample survey from multiple provinces and incorporates that in the estimates. All

statistical tests were two-sided, and the level of significance was 5%. Statistical analyses were performed using SAS (version 9.4, SAS Institute Inc., Cary, NC, USA).

RESULTS

Participant Characteristics

In total, 1,160 patients were included, and 52.2% were male, with age [median (Q1, Q3)] of 46.0 (33.0, 57.0) years. There were 341 (29.4%) patients with more than one comorbidity. Among the 1,160 patients, 158 (13.6%) were diagnosed with severe illness and 32 (2.7%) had unfavorable outcomes at the end of the two-week follow-up window. Patients with severe COVID-19 were older than those with non-severe COVID-19 (median: 57.0 vs. 44.0 years), and patients who had unfavorable outcomes were older than those with favorable outcomes (median: 60.0 vs. 46.0 years). Patients who were > 60 years of age had a higher percentage of severe illness, comorbidity, and unfavorable outcomes. Cough (49.8%) and fever (44.7%) were the two most common onset symptoms. Overall, patients with symptoms (except sore throat) had a higher percentage of severe illness and unfavorable outcomes (Table 1).

Hypertension (16.2%), T2DM (7.7%), and CVD (6.3%) were the three most common comorbidities. Other lung diseases (2.3%) and hepatitis B (2.1%) were common comorbidities of non-cardiometabolic disease. Around one-third of patients had one or more comorbidities (Table 2). The distribution of clinical severity and treatment outcome in the un-overlapped component of comorbidities are listed in [Supplementary Table S1](#) (available in www.besjournal.com).

In addition, 1,109 (95.6%) patients received treatment with combination of Chinese and Western medicine during hospitalization, 1,012 (91.3%) patients received Qingfei Paidu decoction of Chinese medicine, and 25 (2.4%) had unfavorable outcomes. However, 2.7% of unfavorable outcomes among all patients.

Types of Comorbidity and Clinical Severity and Treatment Outcome

Compared with patients with no comorbidities, patients with any comorbidity had > 3-fold higher odds of being severely ill (*OR*, 3.55; 95% *CI*, 1.94–6.50) and having unfavorable outcomes (3.65, 2.23–5.98). Patients with hypertension, T2DM, and

CVD (either heart diseases or stroke) had higher odds of being severely ill, with *OR* (95% *CI*) of 3.40 (1.70, 6.80), 3.36 (1.95, 5.77), and 3.65 (2.21, 6.03), respectively. They were also more likely to have unfavorable treatment outcomes, with *OR* (95% *CI*) of 2.34 (1.44, 3.80), 4.12 (2.20, 7.72), and 4.45 (2.14, 9.26), respectively. Patients with fatty liver disease and hyperlipidemia also had an increased odd of being severely ill, although their 95% *CI* spanned one (Table 3).

In terms of non-cardiometabolic disease, other lung diseases (4.96, 2.51–9.80), tuberculosis (2.89, 1.85–4.54), electrolyte imbalance (15.33, 3.54–66.40), and abnormal liver/kidney function (6.83, 1.44–32.48) were linked to elevated odds of having severe illness. The latter two also had higher odds of having unfavorable treatment outcomes, with *OR* (95% *CI*) of 12.49 (5.52, 28.28) and 7.69 (2.01, 29.41), respectively (Table 3). The *ORs* (95% *CI*) between allergic diseases, hepatitis B, tuberculosis, depression, and treatment outcome were not reported due to the small number of patients with these morbidities.

After the associations of un-overlapped components with severity and treatment outcomes were analyzed, hypertension (2.87, 1.30–6.32), T2DM (3.57, 2.32–5.49), CVD (3.78, 1.81–7.89), fatty liver disease (7.53, 1.96–28.96), hyperlipidemia (2.15, 1.26–3.67), other lung diseases (6.00, 3.01–11.96), and electrolyte imbalance (10.40, 3.00–26.10) were independently linked to increased odds of severe illness. T2DM (6.07, 2.89–12.75), CVD (8.47, 6.03–11.89), and electrolyte imbalance (19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes (Table 4).

Number of Comorbidities and Clinical Severity and Treatment Outcome

Compared with patients with no comorbidities, patients with one, two, three, or more comorbidities had increased odds of being severely ill, with *OR* (95% *CI*) of 3.43 (2.06, 5.72), 3.64 (1.07, 11.23), and 5.32 (2.16, 13.10), respectively. They also had elevated odds of having an unfavorable outcome, with *OR* (95% *CI*) of 3.00 (1.53, 5.87), 3.81 (1.60, 9.06), and 5.44 (2.48, 11.91), respectively. A dose-response trend was found between the number of comorbidities and the likelihood of being severely ill or having an unfavorable outcome ($P < 0.001$). Similar results were found when analyses were performed for comorbidities of cardiometabolic diseases or non-cardiometabolic diseases (Table 5).

Table 1. Characteristics of patients by clinical severity, treatment outcome and having comorbidity or not

| Variables | n (%) | Clinical severity | | Treatment outcome | | Comorbidity or not | |
|--------------------------|----------------------|-------------------------------------|-------------------------------|--------------------------------------|-------------------------------------|----------------------|----------------------|
| | | Non-severe cases (%) (n = 1,002) | Severe cases (%) (n = 158) | Favorable outcome (%) (n = 1,128) | Unfavorable outcome (%) (n = 32) | No (%) (n = 819) | Yes (%) (n = 341) |
| Sex | | | | | | | |
| Male | 606 (52.2) | 519 (85.6) | 87 (14.4) | 594 (98.0) | 12 (2.0) | 412 (68.0) | 194 (32.0) |
| Female | 554 (47.8) | 483 (87.2) | 71 (12.8) | 534 (96.4) | 20 (3.6) | 407 (73.5) | 147 (26.5) |
| Age, median (Q1, Q3) | 46.0 (33.0, 57.0) | 44.0 (32.0, 55.0) | 57.0 (45.0, 67.0) | 46.0 (32.0, 56.0) | 60.0 (46.0, 71.0) | 40.0 (30.0, 51.0) | 56.0 (48.0, 65.0) |
| Age (categorized) | | | | | | | |
| < 60 | 917 (79.1) | 828 (90.3) | 89 (9.7) | 901 (98.3) | 16 (1.7) | 717 (78.2) | 200 (21.8) |
| ≥ 60 | 243 (20.9) | 174 (71.6) | 69 (28.4) | 227 (93.4) | 16 (6.6) | 102 (42.0) | 141 (58.0) |
| BMI, Mean (SD) | 23.8 (3.4) | 23.6 (3.3) | 24.9 (3.7) | 23.8 (3.4) | 24.0 (3.2) | 23.5 (3.3) | 24.6 (3.4) |
| Onset symptoms | | | | | | | |
| Fever | | | | | | | |
| No | 641 (55.3) | 575 (89.7) | 66 (10.3) | 631 (98.4) | 10 (1.6) | 462 (72.1) | 179 (27.9) |
| Yes | 519 (44.7) | 427 (82.3) | 92 (17.7) | 497 (95.8) | 22 (4.2) | 357 (68.8) | 162 (31.2) |
| Fatigue | | | | | | | |
| No | 841 (72.5) | 752 (89.4) | 89 (10.6) | 822 (97.7) | 19 (2.3) | 609 (72.4) | 232 (27.6) |
| Yes | 319 (27.5) | 250 (78.4) | 69 (21.6) | 306 (95.9) | 13 (4.1) | 210 (65.8) | 109 (34.2) |
| Cough | | | | | | | |
| No | 582 (50.2) | 533 (91.6) | 49 (8.4) | 573 (98.5) | 9 (1.6) | 424 (72.9) | 158 (27.2) |
| Yes | 578 (49.8) | 469 (81.1) | 109 (18.9) | 555 (96.0) | 23 (4) | 395 (68.3) | 183 (31.7) |
| Congestion or runny nose | | | | | | | |
| No | 1126 (97.1) | 973 (86.4) | 153 (13.6) | 1,096 (97.3) | 30 (2.7) | 780 (70.1) | 332 (29.9) |
| Yes | 34 (2.9) | 29 (85.3) | 5 (14.7) | 32 (94.1) | 2 (5.9) | 39 (81.3) | 9 (18.8) |
| Anorexia | | | | | | | |
| No | 1,032 (89.0) | 909 (88.1) | 123 (11.9) | 1,010 (97.9) | 22 (2.1) | 737 (71.4) | 295 (28.6) |
| Yes | 128 (11.0) | 93 (72.7) | 35 (27.3) | 118 (92.2) | 10 (7.8) | 82 (64.1) | 46 (35.9) |
| Sore throat | | | | | | | |
| No | 1,046 (90.2) | 895 (85.6) | 151 (14.4) | 1,014 (96.9) | 32 (3.1) | 734 (70.2) | 312 (29.8) |
| Yes | 114 (9.8) | 107 (93.9) | 7 (6.1) | 114 (100) | 0 (0.0) | 85 (74.6) | 29 (25.4) |
| Diarrhea | | | | | | | |
| No | 1,113 (95.9) | 963 (86.5) | 150 (13.5) | 1,084 (97.4) | 29 (2.6) | 787 (70.7) | 326 (29.3) |
| Yes | 47 (4.1) | 39 (83) | 8 (17.0) | 44 (93.6) | 3 (6.4) | 32 (68.1) | 15 (31.9) |
| Shortness of breath | | | | | | | |
| No | 1,027 (88.5) | 917 (89.3) | 110 (10.7) | 1,004 (97.8) | 23 (2.2) | 735 (71.6) | 292 (28.4) |
| Yes | 133 (11.5) | 85 (63.9) | 48 (36.1) | 124 (93.2) | 9 (6.8) | 84 (63.2) | 49 (36.8) |
| Chills | | | | | | | |
| No | 1,095 (94.4) | 951 (86.9) | 144 (13.2) | 1,065 (97.3) | 30 (2.7) | 780 (71.2) | 315 (28.8) |
| Yes | 65 (5.6) | 51 (78.5) | 14 (21.5) | 63 (96.9) | 2 (3.1) | 39 (60.0) | 26 (40.0) |
| Ever went to Wuhan city | | | | | | | |
| No | 658 (56.7) | 572 (86.9) | 86 (13.1) | 636 (96.7) | 22 (3.3) | 450 (68.4) | 208 (31.6) |
| Yes | 322 (27.8) | 287 (89.1) | 35 (10.9) | 315 (97.8) | 7 (2.2) | 235 (73.0) | 87 (27.0) |

Note. Q1, the first quartile; Q3, the third quartile; SD, standard deviation.

Comorbidity and Clinical Severity and Treatment Outcome in Subgroups

Women with comorbidities (*OR*, 5.46; 95% *CI*, 3.25–9.19) had higher odds of being severely ill than men with comorbidities did (2.46, 1.15–5.28), while men (6.58, 1.46–29.64) with comorbidities had a higher likelihood of having an unfavorable outcome than women did (2.38, 1.78–3.19). In patients aged

> 60 years, CVD was highly associated with an unfavorable outcome (5.39, 1.74–16.68), and in patients aged < 60 years, T2DM was strongly correlated with unfavorable outcomes (8.03, 2.26–28.55) (Table 6).

DISCUSSION

Our findings indicate that COVID-19 patients with

Table 2. Distribution of clinical severity and treatment outcome of COVID-19 by component and number of comorbidities

| Variables | n (%) | Clinical severity | | | Treatment outcome | | |
|--|------------|----------------------|------------------|------------------|-----------------------|-------------------------|------------------|
| | | Non-severe cases (%) | Severe cases (%) | <i>P</i> value * | Favorable outcome (%) | Unfavorable outcome (%) | <i>P</i> value * |
| No comorbidity at all | 819 (70.6) | 758 (92.6) | 61 (7.4) | | 808 (98.7) | 11 (1.3) | |
| Had any comorbidity | 341 (29.4) | 244 (71.6) | 97 (28.4) | < 0.0001 | 320 (93.8) | 21 (6.2) | < 0.0001 |
| Comorbidity of cardiometabolic diseases | | | | | | | |
| Hypertension | 188 (16.2) | 136 (72.3) | 52 (27.7) | < 0.0001 | 179 (95.2) | 9 (4.8) | 0.0023 |
| T2DM | 89 (7.7) | 65 (73.0) | 24 (27.0) | < 0.0001 | 83 (93.3) | 6 (6.7) | 0.0004 |
| Heart disease | 53 (4.6) | 32 (60.4) | 21 (39.6) | < 0.0001 | 44 (83.0) | 9 (17.0) | < 0.0001 |
| Stroke | 24 (2.1) | 18 (75.0) | 6 (25.0) | 0.0017 | 22 (91.7) | 2 (8.3) | 0.0501 |
| CVD (either heart disease or stroke) | 73 (6.3) | 47 (64.4) | 26 (35.6) | < 0.0001 | 63 (86.3) | 10 (13.7) | < 0.0001 |
| Fatty liver | 8 (0.7) | 6 (75.0) | 2 (25.0) | 0.0626 | 8 (100.0) | – | – |
| Hyperlipidemia | 9 (0.8) | 7 (77.8) | 2 (22.2) | 0.0964 | 9 (100.0) | – | – |
| Hyperuricemia | 7 (0.6) | 6 (85.7) | 1 (14.3) | 0.4220 | 6 (85.7) | 1 (14.3) | 0.0977 |
| Had hypertension and T2DM together | 38 (3.3) | 27 (71.1) | 11 (28.9) | < 0.0001 | 36 (94.7) | 2 (5.3) | 0.1098 |
| Had hypertension and CVD together | 37 (3.2) | 23 (62.2) | 14 (37.8) | < 0.0001 | 32 (86.5) | 5 (13.5) | < 0.0001 |
| Had CVD and T2DM together | 17 (1.5) | 12 (70.6) | 5 (29.4) | 0.0009 | 17 (100.0) | – | – |
| Had hypertension, CVD and T2DM together | 12 (1.0) | 8 (66.7) | 4 (33.3) | 0.0009 | 12 (100.0) | – | – |
| Comorbidity of non-cardiometabolic disease | | | | | | | |
| Other lung diseases | 27 (2.3) | 15 (55.6) | 12 (44.4) | < 0.0001 | 26 (96.3) | 1 (3.7) | 0.3242 |
| Allergic diseases | 7 (0.6) | 1 (14.3) | 6 (85.7) | < 0.0001 | 7 (100.0) | – | – |
| Hepatitis B | 24 (2.1) | 22 (91.7) | 2 (8.3) | 0.8709 | 24 (100.0) | – | – |
| Pulmonary tuberculosis | 9 (0.8) | 7 (77.8) | 2 (22.2) | 0.0964 | 9 (100.0) | – | – |
| Electrolyte disturbance | 16 (1.4) | 7 (43.8) | 9 (56.3) | < 0.0001 | 12 (75.0) | 4 (25.0) | 0.0001 |
| Abnormal liver or kidney function | 17 (1.5) | 9 (52.9) | 8 (47.1) | < 0.0001 | 15 (88.2) | 2 (11.8) | 0.0266 |
| Depression | 6 (0.5) | 5 (83.3) | 1 (16.7) | 0.3751 | 6 (100) | – | – |
| Number of any comorbidity | | | | | | | |
| 0 | 819 (70.6) | 758 (92.6) | 61 (7.5) | | 808 (98.7) | 11 (1.3) | |
| 1 | 230 (19.8) | 168 (73.0) | 62 (27.0) | < 0.0001 | 218 (94.8) | 12 (5.2) | < 0.0001 |
| 2 | 83 (7.2) | 59 (71.1) | 24 (28.9) | | 77 (92.8) | 6 (7.2) | |
| 3 | 28 (2.4) | 17 (60.7) | 11 (39.3) | | 25 (89.3) | 3 (10.7) | |

Note. T2DM, type 2 diabetes; CVD, cardiovascular disease. **P* values were calculated by comparing the distribution of severity and treatment outcome in patients with no comorbidity at all group.

hypertension, T2DM, CVD, fatty liver disease, and hyperlipidemia were more likely to have severe illness on admission, and the first three diseases were also predicted to have unfavorable treatment outcomes. Besides, other lung diseases and electrolyte imbalance were strong independent risk factors for COVID-19 severity and unfavorable outcomes. There was a dose-response trend between the number of comorbidities and severity or unfavorable treatment outcome. Women with comorbidities were more likely to be severe on admission, while men with comorbidities were more likely to have unfavorable treatment outcomes

within two weeks.

Two systematic reviews have reported that the most prevalent comorbidities were hypertension (16.4%–21.1%), diabetes (7.9%–9.7%), CVD (8.4%–12.1%), and respiratory system disease (1.5%)^[8,9]. However, no other comorbidities were reported. In addition to observing a similar prevalence of cardiometabolic diseases, we also reported the prevalence of hepatitis B (2.1%) and tuberculosis (0.8%) because some studies have reported a coinfection of hepatitis B, tuberculosis, and COVID-19^[10,11]. In addition, previous studies have reported various electrolyte abnormalities on admission in

Table 3. The odds ratio and 95% confidence interval (OR, 95% CI) between comorbidities and clinical severity and treatment outcome of COVID-19: components were overlapped

| Variables | Severe illness* | | Unfavorable outcome† | |
|--|---------------------|---------------------|----------------------|---------------------|
| | Unadjusted OR | Adjusted OR | Unadjusted OR | Adjusted OR |
| No comorbidity at all | Ref | Ref | Ref | Ref |
| Had any comorbidity | 4.94 (2.91, 8.39) | 3.55 (1.94, 6.50) | 4.82 (2.77, 8.40) | 3.65 (2.23, 5.98) |
| Comorbidity of cardiometabolic disease | | | | |
| Hypertension | 4.75 (2.61, 8.66) | 3.40 (1.70, 6.80) | 3.69 (2.18, 6.26) | 2.34 (1.44, 3.80) |
| T2DM | 4.59 (2.72, 7.74) | 3.36 (1.95, 5.77) | 5.31 (2.90, 9.72) | 4.12 (2.20, 7.72) |
| Heart disease | 8.16 (4.86, 13.71) | 4.24 (2.36, 7.62) | 15.03 (9.85, 22.92) | 6.31 (3.63, 10.98) |
| Stroke | 4.14 (1.60, 10.70) | 3.44 (1.22, 9.66) | 6.68 (2.00, 22.34) | 1.84 (0.33, 10.23) |
| CVD (either heart disease or stroke) | 6.87 (4.28, 11.05) | 3.65 (2.21, 6.03) | 11.66 (8.17, 16.64) | 4.45 (2.14, 9.26) |
| Fatty liver | 4.14 (0.95, 18.15) | 3.41 (0.91, 12.75) | – | – |
| Hyperlipidemia | 3.55 (1.67, 7.56) | 1.76 (0.97, 3.20) | – | – |
| Hyperuricemia | 2.07 (0.17, 25.61) | 1.31 (0.1, 17.63) | – | – |
| Had hypertension and T2DM together | 5.06 (2.61, 9.84) | 3.01 (1.19, 7.62) | 4.08 (1.13, 14.76) | 2.51 (0.71, 8.86) |
| Had hypertension and CVD together | 7.56 (3.76, 15.23) | 4.52 (2.59, 7.87) | 11.48 (4.90, 26.87) | 3.96 (0.98, 16.02) |
| Had CVD and T2DM together | 5.18 (1.07, 25.00) | 3.93 (0.97, 15.94) | – | – |
| Had hypertension, CVD and T2DM together | 6.21 (1.38, 27.90) | 4.0 (1.22, 13.16) | – | – |
| Comorbidity of non-Cardiometabolic disease | | | | |
| Other lung diseases | 9.94 (6.61, 14.96) | 4.96 (2.51, 9.80) | 2.83 (0.57, 14.13) | 2.11 (0.46, 9.80) |
| Allergic diseases | – | – | – | – |
| Hepatitis B | 1.13 (0.63, 2.03) | 0.83 (0.51, 1.37) | – | – |
| Pulmonary tuberculosis | 3.55 (2.19, 5.76) | 2.89 (1.85, 4.54) | – | – |
| Electrolyte disturbance | 15.98 (4.41, 57.95) | 15.33 (3.54, 66.40) | 15.59 (4.80, 50.66) | 12.49 (5.52, 28.28) |
| Abnormal liver/kidney function | 11.05 (3.68, 33.18) | 6.83 (1.44, 32.48) | 9.79 (2.29, 41.89) | 7.69 (2.01, 29.41) |
| Depression | – | – | – | – |

Note. * Patients who were diagnosed as non-severe were used as reference group. † Patients who had favorable outcome at end of follow-up window were used as reference group. T2DM, type 2 diabetes; CVD, cardiovascular disease. A short dash ‘–’ was used when there was no statistical power to estimate the association.

patients whose condition progresses to the severe COVID-19, including sodium, potassium, chloride, and calcium level abnormalities^[12,13]. In addition, abnormal organ function damage (liver and kidney injuries) was more prevalent in severely ill patients than in mild patients^[14-16]. We also reported the prevalence of electrolyte imbalance (1.4%) and abnormal liver or kidney function (1.5%).

One meta-analysis of hypertension reported that patients with high blood pressure had 2-fold higher odds of developing severe COVID-19 (using the same definition in the present study), than patients without hypertension did (*OR*, 2.27; 95% *CI*, 1.80–2.86)^[17]. A recent study also found that patients with hypertension had a higher risk of unfavorable treatment outcomes (defined as admission to ICU or death) (*HR*, 1.58; 95% *CI*,

1.07–2.32)^[3]. The rates of severe illness of COVID-19 are significantly higher in patients with diabetes than in those without diabetes^[18]. Two recent meta-analyses reported that preexisting diabetes was associated with an approximate 2-fold higher likelihood of having severe/critical COVID-19 illness and about 3-fold increased risk of in-hospital mortality^[19,20]. A large-scale study in the United States found that patients with concomitant coronary artery disease had a higher relative risk (*RR*) of mechanical ventilation (*RR*, 1.88; 95% *CI*, 1.52–2.35) and mortality (2.24, 1.98–2.55)^[21]. In addition, heart disease is independently associated with adverse outcomes irrespective of baseline comorbidities^[22]. Studies also found that people with nonalcoholic fatty liver disease were over six times more likely to develop severe COVID-19 than were

Table 4. The odds ratio and 95% confidence interval (*OR*, 95% *CI*) of comorbidities with clinical severity and treatment outcome of COVID-19: components were un-overlapped

| Variables | Severe illness* | | Unfavorable outcome† | |
|--|----------------------|---------------------|----------------------|----------------------|
| | Unadjusted <i>OR</i> | Adjusted <i>OR</i> | Unadjusted <i>OR</i> | Adjusted <i>OR</i> |
| No comorbidity at all | Ref | Ref | Ref | Ref |
| Comorbidity of cardiometabolic disease | | | | |
| Hypertension | 4.10 (2.04, 8.23) | 2.87 (1.30, 6.32) | 1.19 (0.36, 4.00) | 0.93 (0.27, 3.22) |
| T2DM | 4.39 (2.79, 6.90) | 3.57 (2.32, 5.49) | 7.00 (3.58, 13.69) | 6.07 (2.89, 12.75) |
| CVD (either heart disease or stroke) | 6.83 (3.31, 14.12) | 3.78 (1.81, 7.89) | 14.13 (6.72, 29.70) | 8.47 (6.03, 11.89) |
| Fatty liver | 8.28 (2.02, 33.97) | 7.53 (1.96, 28.96) | – | – |
| Hyperlipidemia | 3.11 (1.60, 6.02) | 2.15 (1.26, 3.67) | – | – |
| Hyperuricemia | – | – | – | – |
| Had hypertension and T2DM together | 4.58 (1.88, 11.13) | 3.04 (0.91, 10.20) | 6.12 (1.42, 26.45) | 4.73 (0.88, 25.37) |
| Had hypertension and CVD together | 8.28 (3.31, 20.74) | 4.65 (2.00, 10.81) | 18.36 (7.01, 48.11) | 9.90 (3.24, 30.25) |
| Had CVD and T2DM together | 3.11 (0.42, 23.02) | 1.96 (0.35, 11.13) | – | – |
| Had hypertension, CVD and T2DM together | 6.21 (1.38, 28.06) | 3.69 (0.86, 15.79) | – | – |
| Comorbidity of non-Cardiometabolic disease | | | | |
| Other lung diseases | 8.28 (4.88, 14.07) | 6.00 (3.01, 11.96) | 5.25 (1.1, 25.02) | 3.89 (0.67, 22.61) |
| Allergic diseases | | | | |
| Hepatitis B | 0.80 (0.30, 2.00) | 0.80 (0.30, 2.35) | – | – |
| Pulmonary tuberculosis | 2.50 (0.60, 9.90) | 1.90 (0.68, 5.08) | – | – |
| Electrolyte disturbance | 12.80 (5.07, 32.23) | 10.40 (3.00, 26.10) | 16.30 (6.60, 40.20) | 19.44 (11.47, 32.96) |
| Abnormal liver/kidney function | 12.40 (0.70, 131.90) | 10.50 (0.59, 87.34) | – | – |
| Depression | – | – | – | – |

Note. * Patients who were diagnosed as non-severe were used as reference group. † Patients who had favorable outcome at end of follow-up window were used as reference group. T2DM, type 2 diabetes; CVD, cardiovascular disease. A short dash ‘–’ was used when there was no statistical power to estimate the association.

Table 5. The odds ratio and 95% confidence interval (*OR*, 95% *CI*) between number of comorbidities and clinical severity and treatment outcome

| Number of comorbidities | Severe case* | | Unfavorable outcome† | |
|---------------------------------------|----------------------|--------------------|----------------------|--------------------|
| | Unadjusted <i>OR</i> | Adjusted <i>OR</i> | Unadjusted <i>OR</i> | Adjusted <i>OR</i> |
| Number of any comorbidity | | | | |
| 0 | Ref | Ref | Ref | Ref |
| 1 | 4.59 (2.80, 7.50) | 3.43 (2.06, 5.72) | 4.04 (2.08, 7.87) | 3.00 (1.53, 5.87) |
| 2 | 5.06 (2.00, 12.83) | 3.64 (1.07, 11.23) | 5.72 (2.04, 16.04) | 3.81 (1.60, 9.06) |
| 3 or more | 8.04 (2.69, 24.07) | 5.32 (2.16, 13.10) | 8.82 (2.44, 31.89) | 5.44 (2.48, 11.91) |
| <i>P</i> -value for trend | | < 0.0001 | | < 0.0001 |
| Number of cardiometabolic disease | | | | |
| 0 | Ref | Ref | Ref | Ref |
| 1 | 4.33 (2.72, 6.90) | 3.10 (1.86, 5.16) | 3.91 (2.02, 7.57) | 2.81 (1.39, 5.68) |
| 2 | 5.06 (2.02, 12.67) | 3.31 (1.17, 9.41) | 6.30 (2.35, 16.85) | 4.24 (1.82, 9.91) |
| 3 or more | 8.04 (2.69, 24.07) | 4.54 (1.57, 13.16) | 8.82 (2.44, 31.90) | 5.01 (2.61, 9.64) |
| <i>P</i> -value for trend | | < 0.0001 | | < 0.0001 |
| Number of non-cardiometabolic disease | | | | |
| 0 | Ref | Ref | Ref | Ref |
| 1 | 5.48 (2.36, 12.76) | 5.00 (2.16, 11.59) | 4.79 (1.57, 14.66) | 3.85 (1.39, 10.66) |
| 2 or more | 8.75 (3.86, 18.84) | 4.94 (2.02, 12.05) | 5.13 (2.67, 9.86) | 2.93 (1.41, 6.09) |

Note. *Patients who were diagnosed as non-severe were used as reference group. †Patients who had favorable outcome at end of follow-up window were used as reference group.

Table 6. The odds ratio and 95% confidence interval (*OR*, 95% *CI*) between types of comorbidities and clinical severity and treatment outcome by gender and age

| Variables | Gender | | Age | |
|------------------------------------|---------------------|--------------------|--------------------|--------------------|
| | Male | Female | <60 | ≥ 60 |
| Being diagnosed as severe illness* | | | | |
| No comorbidity at all | Ref | Ref | Ref | Ref |
| Any comorbidity | 2.46 (1.15, 5.28) | 5.46 (3.25, 9.19) | 3.54 (1.76, 7.13) | 3.26 (1.56, 6.78) |
| Hypertension | 2.12 (0.84, 5.31) | 5.40 (2.98, 9.80) | 3.31 (1.32, 8.32) | 3.05 (1.33, 7.00) |
| T2DM | 1.92 (0.87, 4.23) | 5.86 (3.53, 9.75) | 2.47 (1.69, 3.61) | 3.95 (1.43, 10.89) |
| CVD | 1.94 (0.82, 4.58) | 4.75 (2.49, 9.05) | 1.57 (0.74, 3.37) | 4.25 (2.26, 8.00) |
| Having unfavorable outcome† | | | | |
| No comorbidity at all | Ref | Ref | Ref | Ref |
| Any comorbidity | 6.58 (1.46, 29.64) | 2.38 (1.78, 3.19) | 4.63 (1.40, 15.27) | 2.79 (1.25, 6.21) |
| Hypertension | 3.28 (0.58, 18.53) | 2.11 (1.25, 3.56) | 3.31 (0.76, 14.47) | 2.35 (0.85, 6.54) |
| T2DM | 10.38 (2.62, 41.17) | 2.72 (1.38, 5.35) | 8.03 (2.26, 28.55) | 1.85 (0.49, 6.92) |
| CVD | 3.75 (1.54, 9.12) | 4.97 (1.89, 13.06) | 3.21 (1.19, 8.65) | 5.39 (1.74, 16.68) |

Note. *Patients who were diagnosed as non-severe were used as reference group. †Patients who had favorable outcome at end of follow-up window were used as reference group. T2DM, type 2 diabetes; CVD, cardiovascular disease.

those without nonalcoholic fatty liver disease^[23,24].

Cardiometabolic diseases usually have shared pathologies. A person having one cardiometabolic disease may also have some others simultaneously, especially those with hypertension, T2DM, and CVD. We found consistent results with the previous findings listed above. However, prior studies did not separate cardiometabolic comorbidities that overlapped with each other; thus, the independent role of each specific disease in the severity of COVID-19 could not be analyzed. We found that after considering the overlap among them, fatty liver disease, T2DM, and CVD were stronger risk factors than hypertension was for COVID-19 severity. One possible mechanism between fatty liver disease and COVID-19 severity is that the impaired hepatic innate immune status plays a critical role in COVID-19 outcome^[23]. Consistent with previous studies^[3,4], a dose-response trend was observed between the number of comorbidities and severity of COVID-19.

Evidence has shown that patients with severe COVID-19 tend to have a higher proportion of electrolyte imbalances, such as hypokalemia and hyponatremia, at baseline compared with those with a mild form of the disease^[12,25]. However, no study has examined the association between electrolyte imbalance and severity of COVID-19. Our findings showed that patients with electrolyte imbalance had much higher odds of developing severe COVID-19. A recent systematic review found that COVID-19 patients with COPD had a 2.62-fold higher risk of severe COVID-19 and a 50% higher risk of death than that of COVID-19 patients without comorbidities^[26]. However, not all respiratory diseases progress to COPD. Besides COPD, we also included chronic bronchitis, bronchial asthma, or pneumonia in the present study. Consistent with previous studies^[2,8], we found that preexisting respiratory diseases increased nearly five times the odds of having severe illness and twice the odds of an unfavorable outcome. Studies have reported the coinfection of COVID-19 and tuberculosis^[27,28], which both attack primarily the lungs. People who experienced tuberculosis who now have COVID-19 may have poorer treatment outcomes. Our findings showed that patients who had tuberculosis coinfection and COVID-19 had nearly 3-fold higher odds of having severe COVID-19.

Although we included abnormal liver/kidney function in this study and found a much higher association with COVID-19 severity and unfavorable outcome, it should be noted that liver/kidney

disturbance might be a potential organ injury caused by the COVID-19 infection rather than a comorbidity. Studies have indicated that some patients with COVID-19 show varying levels of liver disease^[29,30] and acute renal injury^[15,31]. Moreover, patients with acute kidney or renal injury have a higher mortality rate compared to other patients^[31].

In the subgroup analyses, we found that men with comorbidities were more likely to have unfavorable outcomes, consistent with the fact that male sex is an independent risk of mortality in COVID-19^[32]. Intriguingly, we also found that women with comorbidities had higher odds of being diagnosed with severe illness on admission than men did (*OR*: 5.46 vs. 2.38). It seems that although women are more vulnerable to comorbidities than men are, and they are less likely to experience unfavorable outcomes such as death.

Study Strengths and Limitations

The main notable strengths of our study are that we demonstrated the association of un-overlapped comorbidities with the severity and treatment outcome of COVID-19. This information helps to identify the independent role of each comorbidity in COVID-19 prognosis and outcome. In addition, performed subgroup analyses by sex and age group, which were not performed in many of the previous studies.

Our study has several limitations. As we collected information from patients' medical records in the hospital, some variables were missing (such as smoking status and educational level), which would cause some residual bias. Second, some comorbidities included in the present study might have been caused by the COVID-19 rather than a preexisting condition before acquiring COVID-19, such as electrolyte imbalance and abnormal liver/kidney function. From this point of view, they might be complications instead of comorbidities. Third, limited by the sample number of patients with unfavorable outcomes, we did not have sufficient statistical power to analyze the association of allergic diseases, hepatitis B, tuberculosis, and depression with treatment outcomes. In addition, we did not have sufficient statistical power to analyze association with mortality in subgroups. Further studies are necessary to analyze the role of comorbidities on severity and mortality with regard to education and ethnicity. Finally, as the prevalence of comorbidities may differ across countries, caution should be exercised when extrapolating our findings to other countries.

Conclusions

In conclusion, the presence of a comorbidity was associated with an increased likelihood of developing severe COVID-19 and having unfavorable treatment outcomes. Hypertension, T2DM, CVD, fatty liver disease, and hyperlipidemia were linked to COVID-19 severity. Other lung diseases and electrolyte imbalance were strong independent risk factors for COVID-19 severity and unfavorable outcomes. Women with comorbidities were more likely to be severe on admission, while men with comorbidities were more likely to have unfavorable treatment outcomes. Identifying patients with different types and numbers of comorbidities may help clinicians to assess the clinical severity on admission and predict the potential treatment outcome in advance, thereby implementing targeted treatment and management of these patients. These patients may also need close monitoring in clinical practice.

ACKNOWLEDGMENTS

We acknowledge the work and contribution of all participants in the present study for their hard work.

CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

AUTHORS' CONTRIBUTIONS

Experiments were conceived and designed by MA Yan, ZHU Dong Shan, SHI Nan Nan, ZHANG Hua Min, WANG Yan Ping, and WANG Yong Yan. Data were inputted by CHEN Ren Bo, LIU Si Hong, and FAN Yi Pin. Patients were enrolled by WU Gui Hui, YANG Pu Ye, BAI Jiang Feng, CHEN Hong, CHEN Li Ying, FENG Qiao, GUO Tuan Mao, HOU Yong, HU Gui Fen, HU Xiao Mei, HU Yun Hong, HUANG Jin, HUANG Qiu Hua, HUANG Shao Zhen, JI Liang, JIN Hai Hao, LEI Xiao, LI Chun Yan, LI Min Qing, LI Qun Tang, LI Xian Yong, LIU Hong De, LIU Jin Ping, LIU Zhang, MA Yu Ting, MAO Ya, MO Liu Fen, NA Hui, WANG Jing Wei, SONG Fang Li, SUN Sheng, WANG Dong Ting, WANG Ming Xuan, WANG Xiao Yan, WANG Yin Zhen, WANG Yu Dong, WU Wei, WU Lan Ping, XIAO Yan Hua, XIE Hai Jun, XU Hong Ming, XU Shou Fang, XUE Rui Xia, YANG Chun, YANG Kai Jun, YUAN Sheng Li, ZHANG Gong Qi, ZHANG Jin Bo, ZHANG Lin Song, ZHAO Shu Sen, ZHAO Wan Ying, ZHENG Kai, ZHOU Ying chun, ZHU Jun Teng, ZHU

Tian Qing. Data analysis was carried out by MA Yan and ZHU Dong Shan. The paper was written by MA Yan, ZHU Dong shan, CHEN Ren Bo, SHI Nan Nan, and LIU Si Hong.

Received: November 19, 2020;

Accepted: November 30, 2020

REFERENCES

1. Wang DW, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*, 2020; 323, 1061–9.
2. Wang BL, Li RB, Lu Z, et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. *Aging*, 2020; 12, 6049–57.
3. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J*, 2020; 55, 2000547.
4. Ye CY, Zhang SY, Zhang XL, et al. Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang, China. *J Med Virol*, 2020; 92, 2821–9.
5. Nickel CH, Rueegg M, Pargger H, et al. Age, comorbidity, frailty status: effects on disposition and resource allocation during the COVID-19 pandemic. *Swiss Med Wkly*, 2020; 150, w20269.
6. Wei PF. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). *Chin Med J*, 2020; 133, 1087–95.
7. He Y, Pan A, Wang YY, et al. Prevalence of overweight and obesity in 15.8 million men aged 15–49 years in rural China from 2010 to 2014. *Sci Rep*, 2017; 7, 5012.
8. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis*, 2020; 94, 91–5.
9. Emami A, Javanmardi F, Pirbonyeh N, et al. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. *Arch Acad Emerg Med*, 2020; 8, e35.
10. Tadolini M, Codecasa LR, García-García JM, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. *Eur Respir J*, 2020; 96, 2001398.
11. Chen L, Huang S, Yang J, et al. Clinical characteristics in patients with SARS-CoV-2/HBV co-infection. *J Viral Hepat*, 2020; 27, 1504–7.
12. Lippi G, South AM, Henry BM. Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19). *Ann Clin Biochem*: *Int J Lab Med*, 2020; 57, 262–5.
13. Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*, 2020; 395, 497–506.
14. Rismanbaf A, Zarei S. Liver and Kidney Injuries in COVID-19 and Their Effects on Drug Therapy; a Letter to Editor. *Arch Acad Emerg Med*, 2020; 8, e17.
15. Zaim S, Chong JH, Sankaranarayanan V, et al. COVID-19 and Multiorgan Response. *Curr Probl Cardiol*, 2020; 45, 100618.
16. Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. *JAMA Cardiol*, 2020; 5, 831–40.
17. Zhang JQ, Wu J, Sun XH, et al. Association of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis. *Epidemiol Infect*, 2020; 148, e106.
18. Sardu C, Gargiulo G, Esposito G, et al. Impact of diabetes

- mellitus on clinical outcomes in patients affected by Covid-19. *Cardiovasc Diabetol*, 2020; 19, 76.
19. Wu ZH, Tang Y, Cheng Q. Diabetes increases the mortality of patients with COVID-19: a meta-analysis. *Acta Diabetol*, 2020; Epub ahead of print.
 20. Mantovani A, Byrne CD, Zheng MH, et al. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. *Nutr Metab Cardiovasc Dis*, 2020; 30, 1236–48.
 21. Kuno T, Takahashi M, Obata R, et al. Cardiovascular comorbidities, cardiac injury, and prognosis of COVID-19 in New York City. *Am Heart J*, 2020; 226, 24–5.
 22. Lorente-Ros A, Monteagudo Ruiz JM, Rincón LM, et al. Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients. *Cardiol J*, 2020; 27, 489–96.
 23. Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. *Gut*, 2020; 69, 1545–7.
 24. Ji D, Qin EQ, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. *J Hepatol*, 2020; 73, 451–3.
 25. Chen D, Li XK, Song QF, et al. Assessment of Hypokalemia and Clinical Characteristics in Patients With Coronavirus Disease 2019 in Wenzhou, China. *JAMA Netw Open*, 2020; 3, e2011122.
 26. Singh AK, Gillies CL, Singh R, et al. Prevalence of comorbidities and their association with mortality in patients with COVID-19: A Systematic Review and Meta-analysis. *Diabetes Obes Metab*, 2020; 22, 1919–24.
 27. Cutler T, Scales D, Levine W, et al. A Novel Viral Epidemic Collides with an Ancient Scourge: COVID-19 Associated with Tuberculosis. *Am J Respir Crit Care Med*, 2020; 202, 748–9.
 28. Kumar R, Bhattacharya B, Meena V, et al. COVID-19 and TB co-infection - 'Finishing touch' in perfect recipe to 'severity' or 'death'. *J Infect*, 2020; 81, e39–e40.
 29. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol*, 2020; 5, 428–30.
 30. Xu Z, Shi L, Wang YJ, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med*, 2020; 8, 420–2.
 31. Cheng YC, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Intl*, 2020; 97, 829–38.
 32. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ*, 2020; 369, m1985.

Supplementary Table S1. Distribution of clinical severity and treatment outcome of COVID-19 by component and number of comorbidities (un-overlapped)

| Variables | n (%) | Clinical severity | | | Treatment outcome | | |
|--|-------|-------------------|--------------|----------|-------------------|---------------------|----------|
| | | Non-severe cases | Severe cases | P value | Favorable outcome | Unfavorable outcome | P value |
| No comorbidity at all | 819 | 758 (92.6) | 61 (7.5) | | 808 (98.7) | 11 (1.3) | |
| Comorbidity of cardiometabolic diseases | | | | | | | |
| Hypertension | 125 | 94 (75.2) | 31 (24.8) | < 0.0001 | 123 (98.4) | 2 (1.6) | 0.6863 |
| T2DM | 46 | 34 (73.9) | 12 (26.1) | < 0.0001 | 42 (91.3) | 4 (8.7) | 0.0002 |
| CVD | 31 | 20 (64.5) | 11 (35.5) | < 0.0001 | 26 (83.9) | 5 (16.1) | < 0.0001 |
| Fatty liver | 5 | 3 (60.0) | 2 (40.0) | 0.0457 | 5 (100.0) | 0 (0.0) | - |
| Hyperlipidemia | 5 | 4 (80.0) | 1 (20.0) | 0.2763 | 5 (100.0) | 0 (0.0) | - |
| Hyperuricemia | 2 | 2 (100.0) | 0 (0.0) | - | 2 (100.0) | 0 (0.0) | - |
| Hypertension + CVD | 25 | 15 (60.0) | 10 (40.0) | < 0.0001 | 20 (80.0) | 5 (20.0) | < 0.0001 |
| Hypertension + T2DM | 26 | 19 (73.1) | 7 (26.9) | 0.0031 | 24 (92.3) | 2 (7.7) | 0.0577 |
| CVD + T2DM | 5 | 4 (80.0) | 1 (20.0) | 0.2763 | 5 (100.0) | 0 (0.0) | - |
| Hypertension+ CVD + T2DM | 12 | 8 (66.7) | 4 (33.3) | 0.0092 | 12 (100.0) | 0 (0.0) | - |
| Comorbidity of non-cardiometabolic disease | | | | | | | |
| Other lung diseases | 15 | 9 (60.0) | 6 (40.0) | < 0.0001 | 14 (93.3) | 1 (6.7) | 0.1969 |
| Allergic diseases | 4 | 1 (25.0) | 3 (75.0) | 0.0017 | 4 (100.0) | 0 (0.0) | - |
| Hepatitis B | 16 | 15 (93.8) | 1 (6.3) | 0.8563 | 16 (100.0) | 0 (0.0) | - |
| Pulmonary tuberculosis | 6 | 5 (83.3) | 1 (16.7) | 0.3067 | 6 (100.0) | 0 (0.0) | - |
| Electrolyte disturbance | 11 | 6 (54.6) | 5 (45.5) | < 0.0001 | 9 (81.8) | 2 (18.2) | 0.0115 |
| Abnormal liver/kidney function | 2 | 1 (50.0) | 1 (50.0) | 0.1398 | 2 (100.0) | 0 (0.0) | - |
| Depression | 3 | 3 (100.0) | 0 (0.0) | - | 3 (100.0) | 0 (0.0) | - |

Note. T2DM, type 2 diabetes; CVD, cardiovascular disease.